Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Celebrex Clear all
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 25, 2026, 6:36 PM EDT
Terminated Phase 2 Interventional

Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

NCT00084448
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
celecoxib, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects

NCT03282838
View directory record Official record
Conditions
Migraine
Interventions
DFN-15 (fasted), DFN-15 (fed), Comparator Celebrex® (fed)
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 25, 2026, 6:36 PM EDT
Terminated Phase 3 Interventional

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

NCT00087256
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Celecoxib, placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Sep 25, 2026, 6:36 PM EDT
Terminated Phase 4 Interventional

Celebrex Total Knee Arthroplasty Study

NCT00359151
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Aurora, Colorado • Englewood, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 25, 2026, 6:36 PM EDT
Withdrawn Phase 3 Interventional

Multimodal Analgesia in Shoulder Arthroplasty

NCT03586934
View directory record Official record
Conditions
Shoulder Pain, Opioid Use
Interventions
Acetaminophen, Celecoxib 200mg, Celecoxib 400 mg, Ropivacaine, Ketorolac, Acetaminophen Injectable Product, Oxycodone, Tramadol, Morphine Injectable Solution, hydrocodone bitartrate and acetaminophen, Morphine, Oxycodone Hydrochloride, Meloxicam
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 25, 2026, 6:36 PM EDT
Terminated Not applicable Interventional

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

NCT00608595
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, biopsy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B

NCT02413203
View directory record Official record
Conditions
Healthy
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Nonopioid Analgesia After Arthroscopic Meniscus Surgery

NCT03820193
View directory record Official record
Conditions
Meniscus Disorder, Narcotic Use
Interventions
Celecoxib, Hydrocodon/Acetaminophen, Ketorolac, Gabapentin, Acetaminophen, Diazepam
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 25, 2026, 6:36 PM EDT
Terminated Phase 3 Interventional Results available

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

NCT00305643
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Pain
Interventions
Capecitabine, Celecoxib, Radiation Therapy, Placebo
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 2 Interventional

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

NCT00068432
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Celecoxib, Gemcitabine Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
11
States / cities
Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

Celecoxib After Tonsillectomy

NCT02934191
View directory record Official record
Conditions
Tonsillectomy
Interventions
Celecoxib, Placebo, Acetaminophen, Oxycodone
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 11 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 4 Interventional Results available

MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty

NCT02739035
View directory record Official record
Conditions
Stiffness Following Total Knee Arthroplasty
Interventions
Dexamethasone, Celecoxib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
16
States / cities
Little Rock, Arkansas • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy

NCT04429022
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Gabapentin, Acetaminophen, Celecoxib, Ketorolac, Paracervical block with ropivacaine, Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites, Hydromorphone, Oxycodone
Drug · Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
25 Years to 90 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Early Phase 1 Interventional

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

NCT03599453
View directory record Official record
Conditions
Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative, Anatomic Stage IV Breast Cancer AJCC, Progesterone Receptor Negative
Interventions
Biopsy, Chemokine Modulation Therapy, Celecoxib, Recombinant Interferon Alfa-2b, Rintatolimod, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 1 Interventional

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

NCT00346801
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, Cisplatin, CPT-11, Concurrent Thoracic Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2012 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

Toradol v. Celecoxib for Postoperative Pain

NCT03331315
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Celecoxib, Ketorolac
Drug
Lead sponsor
Michael Ulm, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.

NCT00290901
View directory record Official record
Conditions
Back Pain
Interventions
Tramadol Hydrochloride 50mg, Celebrex 200mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 25, 2026, 6:36 PM EDT
Completed No phase listed Observational

Impact of Opioid Avoidance Protocol for ACL Reconstruction

NCT06340932
View directory record Official record
Conditions
ACL Tear, Post Operative Pain
Interventions
Iovera, Celecoxib, Acetaminophen, Oxycodone, Tramadol, Bupivacaine Hydrochloride, Acetaminophen 500Mg Cap
Device · Drug
Lead sponsor
Matthew Varacallo
Other
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
DuBois, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle

NCT00614406
View directory record Official record
Conditions
Ovulation (Follicular Rupture Yes/no), Menstrual Cycles (Total Length, Bleeding Days), Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Interventions
Celebrex, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00081263
View directory record Official record
Conditions
Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Stage 0 Cervical Cancer
Interventions
Celecoxib, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lewes, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 25, 2026, 6:36 PM EDT
Withdrawn Phase 4 Interventional

Single Shot Exparel vs Catheters in Lower Extremity Trauma

NCT07221019
View directory record Official record
Conditions
Fracture Dislocation of Ankle Joint, Fracture Leg, Fracture Femur, Fracture Lower Leg, Fracture
Interventions
Bupivacaine, Exparel + Bupivacaine
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Early Phase 1 Interventional

Window of Opportunity Study Targeting the Inflammatory Milieu

NCT01881048
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Omega-3 fatty acid, Celecoxib
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 25, 2026, 6:36 PM EDT
Completed Phase 4 Interventional Results available

Early Diuresis Following Colorectal Surgery

NCT02351934
View directory record Official record
Conditions
Colorectal Disorders
Interventions
Furosemide, Celecoxib, Gabapentin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 25, 2026, 6:36 PM EDT